Soo Hyun Kim1, Do Hwan Seong2, Sang Min Yoon2, Young Deuk Choi3, Eunju Choi4, Hosook Song5. 1. Department of Nursing, Inha University, Incheon, South Korea. Electronic address: soohyun@inha.ac.kr. 2. Department of Urology, Inha University Hospital and College of Medicine, Inha University, Incheon, South Korea. 3. Department of Urology, Clinical Trials Center for Medical Devices, Yonsei University College of Medicine, Seoul, South Korea. 4. School of Nursing, University of Texas at Austin, TX, USA. 5. Department of Urology, Inha University Hospital, Incheon, South Korea; College of Nursing, Ajou University, Suwon, South Korea.
Abstract
PURPOSE: We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). METHODS: Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). RESULTS: The mean scores were 3.3 (SD = 2.8) for anxiety with a prevalence of 8.9%, 5.7 (SD = 3.8) for depression with a prevalence of 25.5%, and 30.3 (SD = 7.4) for fatigue with a prevalence of 15.6%. The five FACT-P subscale means were 23.9 (SD = 4.3) for physical well-being, 15.4 (SD = 6.4) for social well-being, 18.5 (SD = 4.3) for emotional well-being, 17.3 (SD = 5.6) for functional well-being, and 30.3 (SD = 7.4) for the prostate cancer-specific subscale. Multiple linear regression analysis revealed that depression, which was inversely associated with all FACT-P subscales, was the strongest predictor of worse HRQOL. Fatigue and comorbid conditions were also associated with the HRQOL of multiple domains. CONCLUSION: This study suggests that intervention aimed at improving HRQOL of men receiving ADT should include depression, fatigue, and comorbidity management.
PURPOSE: We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). METHODS: Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). RESULTS: The mean scores were 3.3 (SD = 2.8) for anxiety with a prevalence of 8.9%, 5.7 (SD = 3.8) for depression with a prevalence of 25.5%, and 30.3 (SD = 7.4) for fatigue with a prevalence of 15.6%. The five FACT-P subscale means were 23.9 (SD = 4.3) for physical well-being, 15.4 (SD = 6.4) for social well-being, 18.5 (SD = 4.3) for emotional well-being, 17.3 (SD = 5.6) for functional well-being, and 30.3 (SD = 7.4) for the prostate cancer-specific subscale. Multiple linear regression analysis revealed that depression, which was inversely associated with all FACT-P subscales, was the strongest predictor of worse HRQOL. Fatigue and comorbid conditions were also associated with the HRQOL of multiple domains. CONCLUSION: This study suggests that intervention aimed at improving HRQOL of men receiving ADT should include depression, fatigue, and comorbidity management.